Coherus Oncology, Inc 10-Q for FY2026 Q3
Coherus Oncology, Inc. (CHRS)
10-Q
2026-11-09
For: 2026-09-30
View Original
Added on
November 09, 2026
About this 10-Q
Coherus Oncology, Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Coherus Oncology reported $83.6 million in cash and marketable securities as of September 30, 2026. Management concluded substantial doubt about the company's ability to continue as a going concern remained, citing expected operating losses, negative cash flows and additional funding needs. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $14.27M
- up 23.4% from $11.57M a year earlier
- Net loss
- $39.33M
- compared with a net loss of $35.53M a year earlier
- Diluted EPS
- -$0.25
- compared with -$0.31 a year earlier